Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant